Back to discover
Drug

Ivabradine

Approved · EMA
Emerging researchLate-stage developmentSteady momentum

Also known as Corlanor, Ivabradin, Ivabradina, Ivabradinum.

RxNorm1649480ChEMBLCHEMBL471737UNII3H48L0LPZQ
8
Research papers
6
Active clinical trials
4
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Recall (Class II): IVABRADINE

Regulatory2026-06-04FDA

Recall (Class II): IVABRADINE

Regulatory2026-06-04FDA

Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis: a Prospective, Multicenter, Randomized Controlled Trial

Clinical trial2026-04-24Results expected Q4 2026 · ClinicalTrials.gov

A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Multi-arm, Multi-stage Clinical Trial of Ivabradine for Heart Rate Control In Septic Shock

Clinical trial2026-02-19Primary completion · ClinicalTrials.gov

Heart Rate Control: Betablockers or Ivabradine Therapy Before Cardiac Computed Tomography

Clinical trial2025-12-17Results expected Q3 2028 · ClinicalTrials.gov

RECOVER-AUTONOMIC (Ivabradine): Randomized Trial of the Effect of Ivabradine Versus Placebo on Long COVID Symptoms

Clinical trial2025-12-17Completed · ClinicalTrials.gov

Approval: Ivabradine Anpharm (EMA)

Regulatory2015-09-08EMA

The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients.

Research2015-07-30Rambam Maimonides medical journal

Drug Safety Update: Ivabradine: carefully monitor for bradycardia

Regulatory2014-12-11MHRA

Ivabradine in stable coronary artery disease without clinical heart failure.

Research2014-08-31The New England journal of medicine

Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.

Research2013-09-17American heart journal

Single centre experience of ivabradine in postural orthostatic tachycardia syndrome.

Research2010-11-09Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ivabradine
Aliases & brands
CorlanorIvabradinIvabradinaIvabradinum
RxNorm CUI
1649480
ChEMBL ID
CHEMBL471737
UNII
3H48L0LPZQ
Regulatory jurisdictions
emamhrafda

Regulatory timeline

4 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2015-09-08
Latest approval
2015-09-08
Authorities
FDA · EMA · MHRA
Total events
4
fdaU.S. Food and Drug Administration· 2 events
2026-06-04RecallSafety
Recall (Class II): IVABRADINE
Evidence ↗
2026-06-04RecallSafety
Recall (Class II): IVABRADINE
Evidence ↗
emaEuropean Medicines Agency· 1 event
2015-09-08Approval
Approval: Ivabradine Anpharm (EMA)
Indication: Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults… Show full indication

Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated: in adults unable to tolerate or with a contra-indication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Evidence ↗
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2014-12-11Safety communicationSafety
Drug Safety Update: Ivabradine: carefully monitor for bradycardia
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

74 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
74
registered trials across all phases
LATEST COMPLETION 2025
6
Active studies
4
Recruiting
62
Late-stage (III+)
34
Completed
34
Discontinued
PHASE DISTRIBUTIONn = 74
Phase 11Phase 1 / 21Phase 210Phase 2 / 32Phase 318Phase 429Phase N / A13

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis: a Prospective, Multicenter, Randomized Controlled Trial

RecruitingPH IVSecond Affiliated Hospital of Guangzhou Medical Universityn=1722027

Comparative Cohort Study of Post-acute COVID-19 Infection With a Nested, Randomized Controlled Trial of Ivabradine for Those With Postural Orthostatic Tachycardia Syndrome.

Unknown statusPH IVUniformed Services University of the Health Sciencesn=2502024

Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm - a Randomized Control Trial

CompletedPH IVBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladeshn=422024

Pulse Reduction On Beta-blocker and Ivabradine Therapy

CompletedPH IVUniversity of Colorado, Denvern=282023

Clinical Study of CMR to Evaluate the Effect of Ivabradine on the Improvement of Left Ventricular Remodeling in STEMI Patients After Primary PCI

Unknown statusPH IVQian gengn=2402022

Recent completions

Trials that read out recently, adding to the completed evidence base.

RECOVER-AUTONOMIC (Ivabradine): Randomized Trial of the Effect of Ivabradine Versus Placebo on Long COVID Symptoms

CompletedPH IIKanecia Obie Zimmermann=1812025

Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura: A Randomized Double-Blind Two-Way Crossover Study

CompletedN/ADanish Headache Centern=372025

Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm - a Randomized Control Trial

CompletedPH IVBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladeshn=422024

Comparison Between Atenolol , Propnalol and Ivabradine as a Premedication for Bloodless Field Anesthesia in Lumbar Spine Surgery ,a Prospective Randomized Controlled Trial

CompletedN/AMenoufia Universityn=1202023

Pulse Reduction On Beta-blocker and Ivabradine Therapy

CompletedPH IVUniversity of Colorado, Denvern=282023

A Phase III Clinical Trial to Compare Ivabradine Versus Digoxin in the Heart Rate Control in Patients With Permanent Atrial Fibrillation Under Treatment With Beta-blockers or Calcium Antagonists.

CompletedPH IIIAdolfo Fontenlan=682022

Research activity

8 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20072015
Most influential

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Lancet (London, England) · 2010 · 1,526 cites

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.

Lancet (London, England) · 2010 · 831 cites

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Lancet (London, England) · 2008 · 670 cites

Ivabradine in stable coronary artery disease without clinical heart failure.

The New England journal of medicine · 2014 · 313 cites

Single centre experience of ivabradine in postural orthostatic tachycardia syndrome.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2011 · 69 cites

Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2007 · 24 cites
Recent papers

The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients.

Rambam Maimonides medical journal · 2015 · 22 cites

Ivabradine in stable coronary artery disease without clinical heart failure.

The New England journal of medicine · 2014 · 313 cites

Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.

American heart journal · 2013 · 23 cites

Single centre experience of ivabradine in postural orthostatic tachycardia syndrome.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2011 · 69 cites

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Lancet (London, England) · 2010 · 1,526 cites

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.

Lancet (London, England) · 2010 · 831 cites
Journals, researchers & institutions
Top journals
  • Lancet (London, England)3
  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2
  • American heart journal1
  • Rambam Maimonides medical journal1
  • The New England journal of medicine1
Leading researchers
  • Ford I5
  • Ferrari R3
  • Fox K3
  • Steg PG3
  • Tendera M3
  • Böhm M2
  • Borer JS2
  • Dubost-Brama A2
Leading institutions
free-text, unnormalised
  • From the National Heart and Lung Institute1
  • Institute for Ageing and Health1
  • Institute for Cellular Medicine1
  • J. Recanati Autonomic Dysfunction Center1
  • NHLI Imperial College and ICMS Royal Brompton Hospital1
  • Royal Brompton Hospital1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.